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Abstract
Background—Depression is a major barrier to HIV treatment outcomes.
Objective—Test whether antidepressant management decision support integrated into HIV care 
improves antiretroviral adherence and depression morbidity.
Design—Pseudo-cluster randomized trial.
Setting—Four US infectious diseases clinics.
Participants—HIV-infected adults with major depressive disorder.
Intervention—Measurement-Based Care: depression care managers used systematic metrics to 
give HIV primary-care clinicians standardized antidepressant treatment recommendations.
Measurements—Primary: Antiretroviral medication adherence (monthly unannounced 
telephone-based pill counts for 12m). Primary timepoint: 6m. Secondary: Depressive severity, 
depression remission, depression-free days, measured quarterly for 12m.
Results—From 2010-2013, 149 participants were randomized to intervention and 155 to usual 
care. Participants were mostly male, Black non-Hispanic, unemployed, and virally suppressed 
with high baseline self-reported antiretroviral adherence and depressive severity. Over follow-up, 
no differences between arms in antiretroviral adherence or other HIV outcomes were apparent. At 
6 months, depressive severity was lower among intervention participants than usual care (mean 
difference −3.7 [95% CI: −5.6, −1.7]), probability of depression remission was higher (risk 
difference 13% [1%, 25%]), and suicidal ideation was lower (RD −18% [−30%, −6%]). By 12 
months the arms had comparable mental health outcomes. Intervention arm participants 
experienced an average of 29 (95% CI: 1-57) more depression-free days over 12 months.
Conclusions—In the largest trial of its kind among HIV-infected adults, MBC did not improve 
HIV outcomes, possibly because of high baseline adherence, but achieved clinically significant 
depression improvements and increased depression-free days. MBC may be an effective, resource-
efficient approach to reducing depression morbidity among HIV patients.
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Introduction
Depression is a major barrier to HIV care. Depressive disorders affect an estimated 20-30% 
of people living with HIV[1-3] and are strongly associated with reduced antiretroviral 
(ARV) medication adherence, virologic failure, and higher mortality rates.[4-12]
Depressive disorders are cyclical, with approximately half of depressive episodes resolving 
within 12 months without treatment.[13] However, evidence-based treatments such as 
antidepressants and psychotherapy are critical in speeding the time to recovery and reducing 
depression morbidity.[14] Although such treatments have demonstrated efficacy for HIV-
infected patients,[15, 16] this population still faces a large mental health treatment gap. 
Estimates suggest that among HIV-infected patients with depression, only one in five are 
receiving depression treatment and even fewer are receiving effective (rather than sub-
therapeutic) treatment.[17-19] Evidence is needed on the impact of pragmatic, efficient, 
evidence-based mental health service delivery strategies integrated within HIV primary care.
Despite the associations of depression with adverse HIV outcomes, the impact of effective 
depression treatment on these outcomes is unclear. Several observational studies as well as 
trials of counseling interventions have reported a positive association between receipt of 
depression treatment and ARV adherence,[20-23] while two recent randomized trials of 
medication-based depression treatment found no effect on ARV adherence or other HIV 
outcomes.[24, 25] We report the results of a randomized trial to test the effect of 
Measurement-Based Care, a decision support model for antidepressant management 
integrated into HIV care, on HIV and mental health outcomes among HIV-infected adults 
with depression.
Methods
Study design and objective
The Strategies to Link Antidepressant and Antiretroviral Management at Duke University, 
University of Alabama at Birmingham, Northern Outreach Clinic (Henderson, NC), and 
University of North Carolina (SLAM DUNC) Study was a single-blind randomized 
controlled trial with the objective of testing whether evidence-based decision support for 
antidepressant management, integrated into HIV care, would improve ARV adherence and 
clinical outcomes (ClinicalTrials.gov NCT01372605).[26] English-speaking adults ages 
18-65 receiving HIV care were eligible if they were taking or about to start ARVs, scored 
≥10 on the Patient Health Questionnaire-9 (PHQ-9) depression screening instrument,[27, 
28] and had a major depressive disorder diagnosis confirmed using the Mini International 
Neuropsychiatric Interview (MINI).[29] Patients were excluded who met MINI criteria for 
bipolar or psychotic disorder history, had failed ≥2 antidepressant trials of ≥6 weeks at a 
moderate/high dose during the current depressive episode, were mentally incompetent, or 
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required immediate psychiatric hospitalization. Patients already taking antidepressants were 
eligible if they met other criteria, since despite being on treatment they were currently 
depressed and therefore could plausibly benefit from the active regimen adjustments 
conferred by the intervention.
Conditions
Participants were randomized to Measurement-Based Care (MBC, “intervention”) or 
enhanced treatment as usual (“usual care”). In MBC, depression care managers (DCMs) 
collaborate with medical providers to optimize antidepressant treatment following an 
evidence-based algorithm.[30, 31] MBC emphasizes vigorous antidepressant dosing 
combined with careful monitoring of depressive symptoms and medication tolerability using 
standardized measures. Assessments occur at standardized time points to ensure timely 
assessment of treatment response and subsequent treatment adjustment if indicated.
DCMs in this study were six licensed clinical social workers, one clinical psychologist, and 
one PhD public health researcher. In prior work the DCM role has been filled effectively by 
medical assistants and generalist nurses. DCMs completed a two-day initial training focused 
on diagnosis of depression and excluding diagnoses, response to suicidality, antidepressant 
dosing and side effects, use of standardized MBC tools to assess treatment response and 
tolerability, and use of the MBC algorithm to generate treatment recommendations for HIV 
providers. Ongoing training, quality assurance, and continuous quality improvement 
occurred through weekly group supervision with psychiatric supervisors. Supervisors 
reviewed all DCM patient contacts using a web-based participant registry, focusing on 
review of safety (suicidality) assessments, congruence of treatment recommendations with 
the algorithm and reasons for divergence, pros and cons of specific antidepressants in 
specific situations, and troubleshooting issues such as provider ambivalence about treatment 
adjustments.
In the intervention arm, DCMs met with participants to measure depressive severity 
(PHQ-9[27]) and side effect burden (Frequency, Intensity, and Burden of Side Effects 
Rating scale[32]) at weeks 4, 8, and 12 and, guided by the MBC algorithm, provided 
treatment recommendations to the HIV medical provider (e.g., maintain dose; increase dose; 
change antidepressant).[30] Typically, if depression remission had not been achieved and 
the medication was being tolerated, a dose increase was recommended. If side effects were 
bothersome, possible strategies included dose timing adjustment, dose decrease, or 
medication switch. Side effects were also assessed at interim 2, 6, and 10-week contacts. 
Participants who entered the study already on an antidepressant (but still meeting the 
eligibility criterion of current major depressive disorder) were handled similarly, with an 
initial recommendation to either increase dose or switch medication based on duration, dose, 
and tolerability of current medication. At 12 weeks, participants who had achieved 
remission entered a maintenance phase (3-monthly assessments to confirm continued 
response; if a relapse occurred, a new acute phase cycle was initiated). For non-remitting 
participants, recommendations were made for antidepressant switch/augmentation or an 
optional 4-week extension of the current regimen. All final treatment decisions were the 
purview of the treating HIV provider. Intervention participants also received three 
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motivational interviewing sessions focused on barriers to ARV adherence at 7, 8, and 10 
months, adapted from the PACT intervention.[33] While completion of the PHQ-9 and 
discussion of depressive symptoms and side effects during the DCM assessment sometimes 
led to a broader discussion of the participant's wellbeing, DCMs did not provide any 
structured cognitive-behavioral or other psychotherapeutic depression treatment during 
study contacts.
Usual care was enhanced with initial training of all HIV providers in MBC principles, 
provision of diagnosis information at enrollment, and availability of the MBC algorithm for 
providers to consult on their own. HIV medical providers could prescribe antidepressants or 
refer to mental health services but received no DCM decision support.
Randomization
Pseudo-cluster randomization[34, 35] was employed to balance competing concerns of 
contamination and referral bias.[36] Providers were randomly assigned at baseline to an 
imbalanced case mix of either 80% intervention/20% usual care or 20% intervention/80% 
usual care patients. Using a random number generator, providers were randomized 1:1 in 
blocks of 4 stratified by site and depression treatment experience level. Depression treatment 
experience was assessed at baseline via a semi-structured interview asking about providers’ 
approaches to antidepressant prescription, monitoring of response, and treatment adjustment.
[37] Responses were compared to evidence-based guidelines and scored in standardized 
fashion. For randomization, depression treatment experience was classified as high, 
medium, or low based on tertiles of the resulting total scores.
Each provider was then assigned patient slots in blocks of ten (8 intervention/2 usual care or 
2 intervention/8 usual care, randomly ordered). Provider allocation and patient slot order 
were masked to everyone except the study statistician (BWP). The statistician maintained a 
document showing each provider's next three open slots, with access granted to five 
coordinating center staff with no involvement in enrollment. For each new participant, 
enrollment staff called the coordinating center, identified the participant's provider, and were 
given the arm assignment for that provider's next slot. Regular checks ensured that arm 
assignments were given in the correct order.
Blinding
Blinded research assessors collected all research outcomes. Participants, DCMs, medical 
providers, and investigators were unblinded.
Data collection
The primary outcome was ARV adherence, measured monthly for 12 months by 
unannounced telephone-based pill count. Unannounced telephone-based pill counts have 
been shown to provide valid, accurate measures of adherence[38] and are more sensitive 
than self-report to changes over time.[39] Adherence was calculated as (observed pills 
taken / expected pills taken). “Observed pills taken” was defined as the pills at the previous 
count minus the pills at the current count, corrected for pills gained (e.g. new bottles) or lost 
(e.g. given away) in the interim. “Expected pills taken” was defined as the prescribed 
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number of daily pills times the number of days between counts. Extensive probes about pills 
gained or lost were used to maximize accuracy.
Secondary outcomes included depressive severity (Hamilton Rating Scale for Depression 
[HRSD]),[40-42] depression remission (HRSD<8), self-reported ARV adherence (30-day 
visual analog scale),[43] and HIV-related symptoms (recent headaches, fever, pain in gums, 
white patches in mouth, rashes, nausea, trouble with eyes, sinus pain, numbness in hands or 
feet, cough, diarrhea, or weight loss) ,[1] measured at 3, 6, 9, and 12 months; virologic 
suppression (viral load <50 copies/mL) and physical and mental health-related quality of life 
(SF-12),[44, 45] measured at 6 and 12 months; and depression-free days[46, 47] and HIV 
medical appointment adherence (proportion of kept visits), measured cumulatively over the 
12-month follow-up period. An annualized measure of depression-free days (DFD) was 
calculated by first assigning a value of 1 (depression-free) to HRSD values <8 and a value of 
0 (severely depressed) to HRSD values >21 at each of the 0, 3, 6, 9, and 12-month 
assessments.[46, 47] HRSD scores 8-21 were assigned a proportionately weighted value. To 
annualize DFDs, for each three-month interval the DFD values on each side were averaged 
and multiplied by the interval duration, and then the values for all intervals were summed.
Data quality assurance
Each pill count was reviewed by the original and a second data collector. Pill counts were 
ruled invalid if insufficient information was available to link to the previous count (e.g., >1 
month had elapsed and the number of bottles dispensed was unknown) or if the data 
collector noted substantially conflicting or suspicious information (e.g., hostile behavior; 
open bottles that were not newly dispensed but had not been presented in previous counts). 
If the two reviewers disagreed on validity, all data collectors and the PI jointly reviewed the 
pill count (blinded to arm) and came to consensus.
Sample size
The target sample of 390 (195/arm) was calculated to have 80% power to detect a 10 
percentage point improvement in ARV adherence at 6 months. Power calculations assumed 
pooled standard deviation=25-29%,[22], two-tailed α=0.05, design effect=1.04, 5-10% 
contamination, and 80% 6-month retention. The design effect assumed a mean of 9 patients 
per provider, intraclass correlation coefficient ρ=0.02,[48-51] and an 80%/20% within-
provider intervention allocation ratio in the pseudo-cluster design.[35]
Statistical analysis
The primary time point was defined as 6 months; data collection continued through 12 
months to assess longer-term outcomes. The primary intention-to-treat analysis addressed 
the pseudo-cluster randomization design with clustering by provider and fixed effects for 
site and provider depression treatment experience level. To address missing data, the 
Statistical Analysis Plan, approved by the Data Safety and Monitoring Board, adopted a 
direct modeling approach.[52] Correlates of missingness and earlier (months 1-5) pill count 
measures were modeled as additional outcome variables along with the primary outcome 
using a multivariate normal distribution. If the included correlates of missingness capture the 
important differences between those with and without outcome data, this approach yields an 
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effect estimate corrected for selection bias from the missing data. This approach was 
implemented using linear mixed models with PROC MIXED (SAS 9.3, Cary NC), 
specifying random intercepts for providers and for patients within providers. For secondary 
binary outcomes, risk differences were estimated using generalized linear models (identity 
link, binomial error distribution). Since the linear mixed model approach was inappropriate 
for binary outcomes, correction for missing data was implemented using inverse probability 
of observation weighting, with correlates of missingness serving as explanatory variables in 
the weight estimation model (see e-Appendix).
Ethical review
Each site's Institutional Review Board approved all study activities. Equipoise was 
reasonably present with respect to the study's primary endpoint, and providers were free to 
prescribe antidepressants to usual care participants or refer them to other mental health 
services.
Results
Enrollment occurred from April 2010-October 2013 and follow-up continued through April 
2014. As recruitment was slower than expected, the trial ended due to funding constraints 
before achieving full enrollment. A total of 304 participants were randomized to intervention 
(n=149) or usual care (n=155) (Figure 1). Seventy-seven percent of participants had at least 
one valid ARV adherence measure (78% intervention/76% usual care); 60% had a valid 
primary (6-month) outcome measure (58% intervention/61% usual care).
Participants
The majority of participants were 30-55 years, male, black non-Hispanic, and unemployed 
(Table 1). Participants had high depressive severity and prevalence of psychiatric 
comorbidities. Participants had strong HIV clinical indicators and high self-reported ARV 
adherence. There were small differences between arms in certain demographic 
characteristics, but the arms were well balanced on baseline physical and mental health 
measures.
Treatment
Intervention participants had a mean of 8.9 DCM contacts (Table 2). At study enrollment, 
44% of intervention and 40% of usual care participants were already on an antidepressant; 
17% of intervention and 21% of usual care participants were on a moderate/high 
antidepressant dose (as defined previously based on standard dosing guidelines;[30, 53]). 
Antidepressant prescription and moderate/high dosing increased in both arms during the 
study, but more rapidly and substantially in the intervention arm. External mental health 
referrals and non-study treatment sessions were similar between arms.
HIV-related outcomes
When comparing crude (not accounting for design effects or missingness) outcome 
measures by original arm assignment, ARV adherence measured by unannounced telephone-
based pill count was high overall and showed little change in either arm over time (Figure 
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2A). Self-reported ARV adherence, viral load, appointment attendance, HIV-related 
symptoms, physical health-related functioning, emergency department use, and 
hospitalizations were also similar between the arms over time (supplemental figures).
Mental health outcomes
When comparing crude outcome measures by original arm assignment, the arms had 
comparable baseline depressive severity (Figure 2B). Intervention arm scores improved 7 
points at 6 and 12 months. Usual care scores improved 3 points at 6 months and 5 points at 
12 months. Other mental health indicators also showed early gains in the intervention group, 
with the usual care group mostly closing the gap by 12 months (Figure 2C; supplemental 
figures). The intervention group experienced an average of 160 depression-free days during 
the 12 months of follow-up compared to 136 days among usual care participants.
Effect estimates
In intent-to-treat analyses adjusted for design elements and corrected for missingness, no 
effect was evident on ARV adherence (the primary outcome) or other HIV-related outcomes 
at the primary time point, 6 months (Table 3). At the primary 6-month time point, the 
intervention demonstrated an effect on depressive severity, achievement of depression 
remission, and suicidality as well as a trend toward an effect on mental health-related 
functioning. By 12 months the usual care group had achieved comparable mental health 
outcomes to the intervention group on most indicators, but participants in the intervention 
group maintained their advantage in depression remission (relative advantage of 16.0 [2.6, 
29.4] percentage points) (data not shown). Over 12 months, the intervention arm 
experienced 29 (1, 57) more depression-free days. Correction for missing data had little 
impact on most effect estimates.
Secondary comparisons
In pre-specified secondary comparisons, there was no evidence of stronger intervention 
effectiveness in an “as treated” analysis (ignoring arm and comparing those who had vs. had 
not been on antidepressants for ≥90 days) or a “completers” analysis (ignoring arm and 
comparing those who did vs. did not complete ≥3 treatment adjustment contacts with the 
DCM) (data not shown). There was no evidence of stronger intervention effectiveness in 
pre-specified subgroups (those with baseline self-reported adherence <80%, unsuppressed 
HIV RNA viral load, PHQ-9≥20, or comorbid anxiety/substance use disorders) (data not 
shown).
Discussion
This study represents the largest trial to date of a collaborative care antidepressant 
management intervention integrated into HIV primary care, and the first such trial to our 
knowledge outside of the Veterans Administration (VA) system. The Measurement-Based 
Care depression management approach was effectively integrated in 4 HIV clinics, with 
high uptake of antidepressants and timely dose escalation in the intervention arm. No 
differences between arms were observed in the primary outcome – antiretroviral adherence – 
or other HIV outcomes, including HIV symptoms, viral load, or appointment adherence. At 
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6 months, relative to usual care, the intervention had reduced depressive severity by a 
clinically meaningful margin, increased depression remission, reduced suicidality, and 
improved mental health-related functioning. By 12 months, the usual care arm had caught up 
on most mental health outcome measures. However, by shortening the course of depressive 
episodes, the intervention conferred nearly an additional month of depression-free days over 
the 12 months of study participation.
Similar to this study, two other randomized trials of antidepressant-focused depression 
treatment strategies reported substantial improvements in mental health measures but no 
effect on HIV-related measures. A trial of directly observed weekly fluoxetine compared to 
referral to standard mental health services among 137 homeless or marginally housed men in 
San Francisco reported a strong effect of the intervention on depression outcomes but no 
statistically significant differences in HIV outcomes.[24] A trial of collaborative care for 
depression relative to usual care among 249 patients at 3 VA HIV clinics found a mental 
health benefit of the intervention at 6 months, but usual care participants had caught up by 
12 months. The intervention lowered HIV symptoms but had no effect on ARV adherence or 
other HIV outcomes.[25] In contrast, three trials of cognitive behavioral therapy for 
depression with integrated adherence counseling (CBT-AD) have shown improvements in 
both depression and adherence among 45 adults with HIV and depression;[22] 89 adults 
with HIV, depression, and injection drug use histories;[54] and 40 Latino adults with HIV 
and depression.[55]
Two differences in the above studies are apparent. First, the three trials that identified an 
effect of depression treatment on ARV adherence[22, 54, 55] were conducted among 
participants with relatively poor adherence or viral suppression at baseline. In contrast, 
participants in the present study and the two trials that did not identify such effects[24, 25] 
had high baseline levels of adherence and rates of viral suppression, potentially introducing 
a ceiling effect on HIV outcomes. Second, the trials that found effects on adherence 
deployed an intervention that explicitly targeted both depression and adherence through 
counseling and/or reminder components, while the present study and the trials that did not 
find such effects primarily targeted depression through medication management.
In contrast to the mixed trial results, most observational studies have reported a positive 
association between depression treatment and ARV adherence. A meta-analysis of 29 
studies encompassing >12,000 individuals estimated that depression treatment improved the 
odds of satisfactory ARV adherence by 83%, with a stronger association among 
observational than experimental studies.[20] Estimates from observational studies may be 
confounded by characteristics that are difficult to measure. For example, among depressed 
patients, those willing to initiate depression treatment may be more compliant with medical 
treatment in general. It is also possible that trials tend to enroll generally compliant patients 
whose adherence has little room to improve, while observational studies are able to include 
patients with a wider distribution of adherence.
Among this study's strengths are its size, multiple sites, duration of follow-up, objective 
adherence measure, rigorous pseudo-cluster randomization design, and high level of fidelity 
to protocol achieved through weekly supervision. An additional strength is the broad 
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inclusion criteria. While many depression treatment trials exclude individuals with anxiety 
or substance use disorders to achieve a “clean” participant pool, this study did not, since 
such a set of participants would bear little resemblance to patients with depression in real-
world HIV care.[56] Similarly, many adherence trials restrict enrollment to individuals with 
low adherence or viral failure, but this study did not, since we sought to estimate the impact 
of a clinic-wide collaborative depression care intervention on HIV outcomes.
A major challenge for this study was missing data. While 77% of participants completed ≥1 
follow-up, 60% had a valid 6-month primary outcome measure. Some of those lost may 
have discontinued ART; this is unknown. Importantly, missingness was balanced between 
arms and sophisticated missing-data correction methods had little impact on effect estimates. 
Loss to follow-up could also be related to clinical comorbidities such as immune 
reconstitution inflammation syndrome (IRIS), although most participants were on stable 
ART at entry, no instances of IRIS were documented during follow-up, and correction for 
baseline clinical status did not substantively change effect estimates. An additional 
limitation is the possibility that contamination may have diluted the true effect size, even 
with the pseudo-cluster design. While there were large differences in antidepressant 
prescription and dose escalation between the arms, these measures did improve somewhat 
among usual care participants over time, suggesting that some of the mental health gains of 
the usual care group by 12 months could be explained by contamination. Alternatively, this 
convergence could simply reflect the episodic nature of depressive disorders, for which 
treatment shortens the course of illness but up to 50% of episodes resolve spontaneously 
within a year.[13]
Depression is highly prevalent among people living with HIV.[57, 58] Despite the known 
efficacy of depression treatments in this population,[15, 16] depression remains widely 
under-diagnosed and untreated or under-treated in HIV primary care.[17, 18] New care 
models that build on the success of collaborative depression treatment in general primary 
care[59] are critically needed to address the large mental health treatment gap among people 
living with HIV. Models such as Measurement-Based Care efficiently leverage clinic staff 
time to provide antidepressant prescription decision support to HIV medical providers. This 
trial demonstrates that such a real-world strategy can significantly shorten the course of 
depressive illness for HIV patients and reduce overall morbidity from depression.
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Total PHQ-9 screens and positive screens include multiple screens per patient. Participants 
were defined as receiving the allocated intervention if their provider received at least one 
antidepressant treatment recommendation from the depression care manager (intervention 
arm) or received no antidepressant treatment recommendations from the depression care 
manager (usual care arm).
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HIV medication adherence (A), depressive severity (B), and suicidality (C) over time by 
study arm (uncorrected for design or missing data).
PENCE et al. Page 16

























PENCE et al. Page 17
Table 1
Comparison of baseline participant characteristics by study arm assignment.
Intervention (n = 149) Usual care (n = 155)
% (n) Mean (SD) % (n) Mean (SD)
Sociodemographics
Age (years) 42.8 (10.3) 44.9 (9.9)
Present sex
    Male 75% (112) 64% (100)
    Female 24% (35) 34% (52)
    Transgender and other 1% (2) 2% (3)
Sexual orientation
    Heterosexual 40% (58) 53% (81)
    Gay/Lesbian 46% (67) 34% (51)
    Bisexual 11% (17) 10% (16)
    Other 3% (4) 3% (4)
Race/ethnicity
    White non-Hispanic 36% (54) 25% (39)
    Black non-Hispanic 56% (83) 68% (105)
    Hispanic 6% (9) 3% (4)
    Other 2% (3) 4% (7)
Employment status
    Employed full time 15% (22) 14% (22)
    Employed part time 12% (17) 13% (20)
    Unemployed 73% (108) 73% (111)
Mental health indicators
Depressive severity (HAM-D) 20.3 (6.9) 19.9 (6.9)
Suicidality 23% (32) 20% (26)
Comorbid anxiety disorder 59% (88) 64% (99)
Comorbid substance use disorder 32% (47) 25% (38)
SF-12 mental functioning score 30.5 (9.4) 30.3 (10.4)
HIV-related indicators
CD4 count, cells/mm3 607 (371) 569 (354)
HIV-RNA viral load <50 copies/mL 69% (91) 68% (98)
Self-reported ARV adherence, % 85.8 (23.3) 87.2 (22.2)
Number of HIV symptoms 5.2 (2.9) 5.1 (3.1)
SF-12 physical functioning score 44.1 (11.8) 43.8 (12.1)
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Table 2
Indicators of mental health treatment by study arm assignment.
Intervention (n = 149) Usual care (n = 155)
Range Mean (SD) or % (n) Range Mean (SD) or % (n)
DCM contacts, 12 months 1-21 8.9 (4.4) n/a n/a
    Duration, weeks 4, 8, 12, minutes 5-165 36 (20) n/a n/a
    Duration, weeks 2, 6, 10, minutes 3-90 23 (17) n/a n/a
On antidepressant
    Baseline 44% (66) 39% (60)
    6 months 79% (112) 53% (78)
    12 months 79% (98) 53% (71)
On moderate to high
*
 antidepressant dose
    Baseline 17% (25) 20% (31)
    6 months 39% (55) 28% (42)
    12 months 37% (46) 33% (44)
Non-study mental health counseling sessions, 12 months
** 0-294 6.9 (29.8) 0-66 4.6 (11.1)
Referred for mental health treatment
*** 20% (30) 18% (28)
Baseline antidepressant
    Citalopram 12% (18) 12% (19)
    Sertraline 5% (7) 4% (6)
    Mirtazapine 5% (7) 3% (5)
    Bupropion 5% (7) 3% (4)
    Fluoxetine 3% (4) 3% (4)
    Venlafaxine 3% (4) 2% (3)
    Other
**** 11% (16) 4% (6)
    Multiple 2% (3) 9% (14)
*
As defined previously based on standard dosing guidelines;[30, 53]e.g. ≥40mg citalopram or ≥100mg sertraline daily.
**
One intervention arm participant started daily outpatient mental health and substance use treatment after study enrollment. Excluding this 
outlying participant, mean (SD) number of mental health counseling sessions in the intervention arm was 4.5 (13.9).
***
Any referral for non-study related mental health treatment within or outside the ID clinic
****
In both arms combined, 6 or fewer participants taking amitriptyline, duloxetine, escitalopram, or paroxetine.
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